Monoclonal Antibodies and Immuno-PET Imaging: An Overview

Year 2023, , 165 - 182, 01.03.2023

Elif Tugce Sarcan , Yekta Özer

https://doi.org/10.55262/fabadeczacilik.1172020

Abstract

Radiopharmaceuticals are radioactive medicines used for imaging and/or therapeutic purposes, consisting of radionuclidic and pharmaceutical parts. While PET and SPECT methods are used for imaging purposes, immuno-PET imaging method has gained popularity, recently. Immuno-PET imaging method, is a combination of PET radionuclides and biomolecules, especially monoclonal antibodies (mAb), proteins, peptides, are frequently used for the imaging of different types of cancer. Radionuclides with long half-lives are generally used in immuno-PET imaging. Long biological half-lives of mAbs is the most important reason to be preferred for immuno-PET imaging. Today, Zirconium-89 (Zr-89), Iodine-124 (I-124) with long half-lives and Copper-64 (Cu-64) and Yttrium-86 (Y-86) radionuclides with relatively long half-lives are preferred in immuno-PET imaging. In this article, studies on Zr-89, Cu-64, I-124 and Y-86-labeled mAbs with long half-life and clinical and preclinical studies were reviewed. Also, comparison of these 4 radionuclides, which are frequently used in the labelling of biomolecules (particularly mAbs) with is included.

Keywords

immuno-PET, Zirconium-89, Copper-64, Yttrium-86, Iodine-124, Monoclonal Antibodies, Imaging

References

• Achmad, A., Hanaoka, H., Yoshioka, H., Yamamoto, S., Tominaga, H., Araki, T., . . . Endo, K. (2012). Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Cancer Sci, 103(3), 600-605. doi:10.1111/j.1349-7006.2011.02166.x
• Aluicio-Sarduy, E., Ellison, P. A., Barnhart, T. E., Cai, W., Nickles, R. J., & Engle, J. W. (2018). PET radiometals for antibody labeling. J Labelled Comp Radiopharm, 61(9), 636-651. doi:10.1002/jlcr.3607
• Anderson, C. J., & Ferdani, R. (2009). Cooper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research. Cancer Biother Radiopharm, 24, 379-394. doi:10.1089=cbr.2009.0674
• Avila-Rodriguez, M. A., Nye, J. A., & Nickles, R. J. (2007). Simultaneous production of high specific activity 64Cu and 61Co with 11.4 MeV protons on enriched 64Ni nuclei. Appl Radiat Isot, 65(10), 1115-1120. doi:10.1016/j.apradiso.2007.05.012
• Barbaros, B., & Dikmen, M. (2015). Cancer Immunotherapy. Erciyes University Journal of the Institute of Science and Technology, 31(4), 177-181.
• Battal, H., & Özer, A. Y. (2021). Copper-64 Radiopharmaceuticals-An Overview. In A. Y. Özer (Ed.), New Trensd in Radiopharmaceuticals (pp. 9-15). Ankara: Türkiye Klinikleri.
• Borjesson, P. K., Jauw, Y. W., Boellaard, R., de Bree, R., Comans, E. F., Roos, J. C., . . . van Dongen, G. A. (2006). Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res, 12(7 Pt 1), 2133-2140. doi:10.1158/1078-0432.CCR-05-2137
• Börjesson, P. K., Jauw, Y. W., de Bree, R., Roos, J. C., Castelijns, J. A., Leemans, C. R., . . . Boellaard, R. (2009). Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. Journal of Nuclear Medicine, 50(11), 1828-1836.
• Breedveld, F. C. (2000a). Therapeutic monoclonal antibodies. Lancet, 355(9205), 735-740. doi:10.1016/s0140-6736(00)01034-5
• Breedveld, F. C. (2000b). Therapeutic monoclonal antibodies. The Lancet, 355(9205), 735-740. doi:10.1016/s0140-6736(00)01034-5
• Cai, W., Chen, K., He, L., Cao, Q., Koong, A., & Chen, X. (2007). Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging, 34(6), 850-858. doi:10.1007/s00259-006-0361-6
• Carrasquillo, J. A., O'Donoghue, J. A., Beylergil, V., Ruan, S., Pandit-Taskar, N., Larson, S. M., . . . Abou-Alfa, G. K. (2018). I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res, 8(1), 20. doi:10.1186/s13550-018-0374-8
• Carrasquillo, J. A., Pandit-Taskar, N., O'Donoghue, J. A., Humm, J. L., Zanzonico, P., Smith-Jones, P. M., . . . Larson, S. M. (2011). (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med, 52(8), 1173-1180. doi:10.2967/jnumed.110.086165
• Crisan, G., Moldovean-Cioroianu, N. S., Timaru, D. G., Andries, G., Cainap, C., & Chis, V. (2022). Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. Int J Mol Sci, 23(9). doi:10.3390/ijms23095023
• Cutler, C. S., Hennkens, H. M., Sisay, N., Huclier-Markai, S., & Jurisson, S. S. (2013). Radiometals for combined imaging and therapy. Chem Rev, 113(2), 858-883. doi:10.1021/cr3003104
• Dijkers, E., Hooge, M. N. L.-d., Kosterink, J. G., Jager, P. L., Brouwers, A. H., Perk, L. R., . . . Vries, E. G. d. (2007). Characterization of 89Zr-trastuzumab for clinical HER2 immunoPET imaging. Journal of Clinical Oncology, 25(18_suppl), 3508-3508. doi:10.1200/jco.2007.25.18_suppl.3508
• Dijkers, E. C., Kosterink, J. G., Rademaker, A. P., Perk, L. R., van Dongen, G. A., Bart, J., . . . Lub-de Hooge, M. N. (2009). Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med, 50(6), 974-981. doi:10.2967/jnumed.108.060392
• Dillman, R. O. (2006). Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin Exp Med, 6(1), 1-12. doi:10.1007/s10238-006-0087-6
• Dilworth, J. R., & Pascu, S. I. (2018). The chemistry of PET imaging with zirconium-89. Chem Soc Rev, 47(8), 2554-2571. doi:10.1039/c7cs00014f
• Divgi, C. R., Pandit-Taskar, N., Jungbluth, A. A., Reuter, V. E., Gönen, M., Ruan, S., . . . Russo, P. (2007). Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol, 8(4), 304-310. doi:10.1016/s1470-2045(07)70044-x
• Drude, N., Tienken, L., & Mottaghy, F. M. (2017). Theranostic and nanotheranostic probes in nuclear medicine. Methods, 130, 14-22. doi:10.1016/j.ymeth.2017.07.004
• Ecker, D. M., Jones, S. D., & Levine, H. L. (2015). The therapeutic monoclonal antibody market. MAbs, 7(1), 9-14. doi:10.4161/19420862.2015.989042
• Ferreira, C. L., Yapp, D. T., Lamsa, E., Gleave, M., Bensimon, C., Jurek, P., & Kiefer, G. E. (2008). Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals. Nucl Med Biol, 35(8), 875-882. doi:10.1016/j.nucmedbio.2008.09.001
• Grubmuller, B., Baum, R. P., Capasso, E., Singh, A., Ahmadi, Y., Knoll, P., . . . Mirzaei, S. (2016). (64)Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. Cancer Biother Radiopharm, 31(8), 277-286. doi:10.1089/cbr.2015.1964
• Herrero Alvarez, N., Bauer, D., Hernandez-Gil, J., & Lewis, J. S. (2021). Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem, 16(19), 2909-2941. doi:10.1002/cmdc.202100135
• Heskamp, S., Raave, R., Boerman, O., Rijpkema, M., Goncalves, V., & Denat, F. (2017). (89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry. Bioconjug Chem, 28(9), 2211-2223. doi:10.1021/acs.bioconjchem.7b00325
• Holland, J., Sheh, Y., Smith-Jones, P., & Lewis, J. (2009). Zr-89 radiolabeling of monoclonal antibodies for immunoPET. Journal of Nuclear Medicine, 50(supplement 2), 497-497.
• Holland, J. P., Divilov, V., Bander, N. H., Smith-Jones, P. M., Larson, S. M., & Lewis, J. S. (2010). 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med, 51(8), 1293-1300. doi:10.2967/jnumed.110.076174
• Holland, J. P., Williamson, M. J., & Lewis, J. S. (2010). Unconventional nuclides for radiopharmaceuticals. Mol Imaging, 9(1), 1-20.
• Holliger, P., & Hudson, P. J. (2005). Engineered antibody fragments and the rise of single domains. Nature Biotechnology, 23(9), 1126-1136. doi:10.1038/nbt1142
• Jauw, Y. W., Menke-van der Houven van Oordt, C. W., Hoekstra, O. S., Hendrikse, N. H., Vugts, D. J., Zijlstra, J. M., . . . van Dongen, G. A. (2016). Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? Front Pharmacol, 7, 131. doi:10.3389/fphar.2016.00131
• Kaur, S., Venktaraman, G., Jain, M., Senapati, S., Garg, P. K., & Batra, S. K. (2012). Recent trends in antibody-based oncologic imaging. Cancer Lett, 315(2), 97-111. doi:10.1016/j.canlet.2011.10.017
• Kenanova, V., & Wu, A. M. (2006). Tailoring Antibodies for Radionuclide Delivery. Expert Opinion on Drug Delivery, 3(1), 53-70. doi:https://doi.org/10.1517/17425247.3.1.53
• Kikuchi, M., Clump, D. A., Srivastava, R. M., Sun, L., Zeng, D., Diaz-Perez, J. A., . . . Ferris, R. L. (2017). Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology, 6(7), e1329071. doi:10.1080/2162402X.2017.1329071
• Knowles, S. M., & Wu, A. M. (2012). Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol, 30(31), 3884-3892. doi:10.1200/jco.2012.42.4887
• Kobayashi, H., Choyke, P. L., & Ogawa, M. (2016). Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology. Curr Opin Chem Biol, 33, 32-38. doi:10.1016/j.cbpa.2016.05.015
• Kumar, K., & Ghosh, A. (2021). Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124. Molecules, 26(2). doi:10.3390/molecules26020414
• Kurihara, H., Hamada, A., Yoshida, M., Shimma, S., Hashimoto, J., Yonemori, K., . . . Tamura, K. (2015). (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res, 5, 8. doi:10.1186/s13550-015-0082-6
• Lamberts, L. E., Menke-van der Houven van Oordt, C. W., ter Weele, E. J., Bensch, F., Smeenk, M. M., Voortman, J., . . . de Vries, E. G. (2016). ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. Clin Cancer Res, 22(7), 1642-1652. doi:10.1158/1078-0432.CCR-15-1272
• Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V., . . . Bander, N. H. (1997). Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res, 57(17), 3629-3634.
• Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., . . . Bander, N. H. (1998). Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res, 58(18), 4055-4060.
• Lövqvist, A., Humm, J., Sheikh, A., Finn, R., Koziorowski, J., Ruan, S., . . . Larson, S. M. (2001). PET Imaging of 86Y-Labeled Anti-Lewis Y Monoclonal Antibodies in a Nude Mouse Model: Comparison Between 86Y and 111In Radiolabels. J Nucl Med, 42, 1281-1287.
• Lubberink, M., & Herzog, H. (2011). Quantitative imaging of 124I and 86Y with PET. Eur J Nucl Med Mol Imaging, 38 Suppl 1(Suppl 1), S10-18. doi:10.1007/s00259-011-1768-2
• Maier, F. C., Wild, A. M., Kirchen, N., Holm, F., Fuchs, K., Schwenck, J., . . . Wiehr, S. (2019). Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA(+) tumors in mice using (64)Cu-radiolabeled monoclonal antibodies. Appl Radiat Isot, 143, 149-155. doi:10.1016/j.apradiso.2018.09.006
• McKnight, B. N., & Viola-Villegas, N. T. (2018). (89) Zr-ImmunoPET companion diagnostics and their impact in clinical drug development. J Labelled Comp Radiopharm, 61(9), 727-738. doi:10.1002/jlcr.3605
• Mikolajczak, R., van der Meulen, N. P., & Lapi, S. E. (2019). Radiometals for imaging and theranostics, current production, and future perspectives. J Labelled Comp Radiopharm, 62(10), 615-634. doi:10.1002/jlcr.3770
• Morais, M., & Ma, M. T. (2018). Site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals. Drug Discov Today Technol, 30, 91-104. doi:10.1016/j.ddtec.2018.10.002
• Nayak, T. K., Garmestani, K., Baidoo, K. E., Milenic, D. E., & Brechbiel, M. W. (2011). PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A''-DTPA-bevacizumab. Int J Cancer, 128(4), 920-926. doi:10.1002/ijc.25409
• Nayak, T. P., & Brechbiel, M. W. (2009). Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges. Bioconjug Chem, 20, 825-841. doi:10.1021/bc800299f
• Nelson, A. L. (2010). Antibody fragments: hope and hype. mAbs, 2(1), 77-83. doi:10.4161/mabs.2.1.10786 O'Donoghue, J. A., Smith-Jones, P. M., Humm, J. L., Ruan, S., Pryma, D. A., Jungbluth, A. A., . . . Larson, S. M. (2011). 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med, 52(12), 1878-1885. doi:10.2967/jnumed.111.095596
• Olafsen, T., Gu, Z., Sherman, M. A., Leyton, J. V., Witkosky, M. E., Shively, J. E., . . . Reiter, R. E. (2007). Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody. J Immunother, 30, 396-405.
• Palm, S., Enmon, R. M., Matei, C., Kolbert, K. S., Xu, S., Zanzonico, P. B., . . . Sgouros, G. (2003). Pharmacokinetics and Biodistribution of 86Y-Trastuzumab for 90Y Dosimetry in an Ovarian Carcinoma Model: Correlative MicroPET and MRI. J Nucl Med, 44, 1148-1155.
• Parakh, S., Lee, S. T., Gan, H. K., & Scott, A. M. (2022). Radiolabeled Antibodies for Cancer Imaging and Therapy. Cancers (Basel), 14(6). doi:10.3390/cancers14061454
• Ping Li, W., Meyer, L. A., Capretto, D. A., Sherman, C. D., & Anderson, C. J. (2008). Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm, 23(2), 158-171. doi:10.1089/cbr.2007.0444
• Povoski, S. P., Hall, N. C., Murrey, D. A., Jr., Sharp, D. S., Hitchcock, C. L., Mojzisik, C. M., . . . Bahnson, R. R. (2013). Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma. Surg Innov, 20(1), 59-69. doi:10.1177/1553350612438416
• Ramogida, C. F., & Orvig, C. (2013). Tumour targeting with radiometals for diagnosis and therapy. Chem Commun (Camb), 49(42), 4720-4739. doi:10.1039/c3cc41554f
• Reddy, S., & Robinson, M. K. (2010). Immuno-positron emission tomography in cancer models. Semin Nucl Med, 40(3), 182-189. doi:10.1053/j.semnuclmed.2009.12.004
• Sarcan, E. T., & Özer, A. Y. (2021). Zirconium-89 radiopharmaceuticals: Current status and future. In A. Y. Özer (Ed.), New Trends in Radiopharmaceuticals. (pp. 16-22). Ankara: Türkiye Klinikleri.
• Sarcan, E. T., Silindir-Gunay, M., Ozer, A. Y., & Hartman, N. (2021). 89Zr as a promising radionuclide and it’s applications for effective cancer imaging. Journal of Radioanalytical and Nuclear Chemistry, 330(1), 15-28. doi:10.1007/s10967-021-07928-0
• Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006). Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov, 5(2), 147-159. doi:10.1038/nrd1957
• Sihver, W., Pietzsch, J., Krause, M., Baumann, M., Steinbach, J., & Pietzsch, H. J. (2014). Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. Pharmaceuticals (Basel), 7(3), 311-338. doi:10.3390/ph7030311
• Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., . . . Fujiwara, Y. (2013). 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. Journal of Nuclear Medicine, 54(11), 1869-1875. doi:10.2967/jnumed.112.118612
• Templar Smith, B. (2012). Polyclonal and Monoclonal Antibodies. In J. Norenbergh (Ed.), Introduction to Diagnostic and Therapeutic Monoclonal Antibodies (Vol. 17): University of New Mexico Health Science Center and Pharmacy Continuing Education.
• Van Dongen, G. A., Huisman, M. C., Boellaard, R., Harry Hendrikse, N., Windhorst, A. D., Visser, G. W., . . . Vugts, D. J. (2015). 89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied? Q J Nucl Med Mol Imaging, 59(1), 18-38.
• van Dongen, G. A., Visser, G. W., Lub-de Hooge, M. N., de Vries, E. G., & Perk, L. R. (2007). Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist, 12(12), 1379-1389. doi:10.1634/theoncologist.12-12-1379
• van Dongen, G. A., & Vosjan, M. J. (2010). Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm, 25(4), 375-385. doi:10.1089/cbr.2010.0812
• Verel, I., Visser, G. W., Boerman, O. C., van Eerd, J. E., Finn, R., Boellaard, R., . . . van Dongen, G. A. (2003). Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm, 18(4), 655-661. doi:10.1089/108497803322287745
• Verel, I., Visser, G. W., Vosjan, M. J., Finn, R., Boellaard, R., & van Dongen, G. A. (2004). High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging, 31(12), 1645-1652. doi:10.1007/s00259-004-1632-8
• Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010). Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease. Chem Rev, 110, 2858-2902.
• Wållberg, H., & Ståhl, S. (2013). Design and evaluation of radiolabeled tracers for tumor imaging. Biotechnol Appl Biochem, 60(4), 365-383. doi:10.1002/bab.1111
• Wong, K. J., Baidoo, K. E., Nayak, T. K., Garmestani, K., Brechbiel, M. W., & Milenic, D. E. (2011). In vitro and in vivo pre-clinical analysis of a F(ab’)2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers. EJNMMI Res, 1.
• Xie, Q., Zhu, H., Wang, F., Meng, X., Ren, Q., Xia, C., & Yang, Z. (2017). Establishing Reliable Cu-64 Production Process: From Target Plating to Molecular Specific Tumor Micro-PET Imaging. Molecules, 22(4). doi:10.3390/molecules22040641
• Zaheer, J., Kim, H., Lee, Y. J., Lim, S. M., & Kim, J. S. (2019). Comparison between Fractionated Dose and Single Dose of Cu-64 Trastuzumab Therapy in the NCI-N87 Gastric Cancer Mouse Model. Int J Mol Sci, 20(19). doi:10.3390/ijms20194708
• Zeng, D., Guo, Y., White, A. G., Cai, Z., Modi, J., Ferdani, R., & Anderson, C. J. (2014). Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice. Mol Pharm, 11(11), 3980-3987. doi:10.1021/mp500004m